Obstructive Lung Disease Market 2018: Major Vendors are GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. Inc. (U.S) and more.

The report on Obstructive Lung Disease Market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. And also covered Market Highlights, Regional Analysis, Segmentation, Key Vendors Research and Methodology. Obstructive Lung Disease Market Report by Disease Type (Asthma, Bronchitis, Copd), By Product Type (Inhalers, Nebulizers), By Drug Class (Combination Drug, Lta, Ics, Saba, Laba), By Route of Administration, By End User and Overall Forecast up to 2023

Global Obstructive Lung Disease Market is expected to grow at a CAGR of approximately 8.5% during the forecast period 2017-2023. Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung manifest due to the narrowing of bronchi which often cause excessive contraction of smooth muscles. The major types of obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Increase in prevalence of COPD and asthma patients, rising geriatric population, increase in pipeline products, growing government and non-government initiatives for spreading awareness are the major factors driving the growth of the global obstructive lung diseases market.

Major Players are:

GlaxoSmithKline (GSK) (U.K)

Novartis AG (Switzerland)

Merck & Co. Inc. (U.S)

Abbott Laboratories

AstraZeneca (U.K)

Roche Holding AG (Switzerland)

Etc.

Access Sample copy @ https://www.marketresearchfuture.com/sample_request/5367 .

The leading market players in the Asthma and COPD Drug focus to expand their business operations in the emerging countries. The companies operating in the market have consistently introduced innovative solutions to enhance their product portfolio. Product approval and clinical trial are observed as the two prominent growth strategies adopted by the key market players.

Segmentation:

The obstructive lung disease is segmented on the basis of disease type, product type, drug class, route of administration and end-users.
On the basis of disease type, the market is segmented into asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD), and others
On the basis of product type market is segmented into inhalers, and nebulizers and others. Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs) and others. Moreover the nebulizers are divided into compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers
On the basis of drug class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Furthermore, the Combination products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others. Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is divided into proair, ventolin, and others.
On the basis of route of administration, market is segmented into oral, inhaler, intravenous, subcutaneous, and others
On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.
Region Wise Analysis:

The global obstructive lung disease market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is projected to hold the largest share of the global obstructive lung disease market due to presence of superior research and development base, strong regional economics, and greater emphasis on disease prevention and wellness by governments.
The European obstructive lung disease market is expected to witness rapid growth owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.
Check Discount @ https://www.marketresearchfuture.com/check-discount/5367 .

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.